The authors concluded that there is some evidence that n-3 long-chain polyunsaturated fatty acid supplementation is associated with a small increase in the duration of pregnancy and in infant head circumference, but the clinical importance of this is unclear and further studies are required. This was a well-conducted review and the authors' cautious conclusions are likely to be reliable.
Participants included in the review
Studies in healthy pregnant women were eligible for inclusion. Studies in women with high-risk pregnancies (in which the mother and/or developing foetus were at higher than normal risk for complications during or after pregnancy and birth) were excluded.
Outcomes assessed in the review
Studies that only assessed biochemical outcomes were excluded. After examining the included studies, the reviewers decided to focus on pregnancy outcomes and growth measures at birth. The review assessed pregnancy outcomes, infant growth outcomes and adverse events. Pregnancy outcomes included the duration of pregnancy, percentage of pre-term deliveries, rates of low birth weight, pre-eclampsia, eclampsia, Caesarean section, gestational diabetes and placental weight. Infant growth outcomes included head circumference, birth weight and length at birth.
How were decisions on the relevance of primary studies made?
One reviewer screened titles and abstracts and identified potentially relevant studies and studies of unclear relevance. Two reviewers independently selected studies from those previously identified. Any disagreements were resolved by 
Assessment of study quality
Two reviewers independently assessed validity using the following criteria: generation of allocation sequence; allocation concealment; blinding of the investigators, participants, outcome assessors and data analysts; intention-to-treat (ITT) analysis; and comprehensiveness of follow-up (80% or more follow-up was considered adequate). Studies were classified according to the risk of bias: low risk (one or fewer criterion not met), medium risk (three or fewer criteria not met), or high risk (more than three criteria not met).
Data extraction
Two reviewers independently extracted the data and resolved any disagreements through discussion. Authors of primary studies were contacted to clarify data, if required. The numbers of events of interest and total number of participants were extracted for dichotomous data, while means and standard deviations were extracted for continuous data. Mean differences were calculated for continuous outcomes and risk ratios were calculated for dichotomous outcomes.
Methods of synthesis
How were the studies combined? Pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated for continuous data, while pooled risk ratios with 95% CIs were calculated for dichotomous data. Fixed-effect models were used in the absence of significant heterogeneity and random-effects models used in its presence. Studies reporting adverse events were combined in narrative. Publication bias was assessed using the test for asymmetry of the funnel plot (described by Egger et al.).
How were differences between studies investigated?
Statistical heterogeneity was assessed using the chi-squared statistic (p<0.05 indicated significant heterogeneity) and the I-squared statistic. A sensitivity analysis was performed by repeating the analysis after excluding studies classified as having a high risk of bias.
Results of the review
Six RCTs (n=1,278) were included.
Only one study was considered to have a low risk of bias. Two studies reported adequate allocation concealment, five studies reported double-blinding, one study reported adequate ITT analysis, three studies reported adequate follow-up rates, and all studies adequately reported withdrawals and drop-outs.
Pregnancy outcomes. Supplementation with n-3 LC-PUFA was associated with a significantly longer duration of pregnancy (WMD 1.57 days, 95% CI: 0.35, 2.78; based on 6 RCTs, n=1,278). No statistically significant heterogeneity was detected (p=0.35, I-squared 10.8%). There were no significant differences between n-3 LC-PUFA and control in the percentage of pre-term deliveries, or rates of low birth weight, pre-eclampsia, eclampsia, Caesarean section, gestational diabetes, or placental weight. No statistically significant heterogeneity was detected for any of these analyses.
Growth measures in infants. Supplementation with n-3 LC-PUFA was associated with significantly greater head circumference than control (WMD 0.26 cm, 95% CI: 0.02, 0.49; based on 4 RCTs, n=729). No statistically significant heterogeneity was detected (p=0.20, I-squared 34.8%). After excluding studies classified as having a high risk of bias, there was no significant difference between supplementation and control (WMD 0.26 cm, 95% CI: -0.02, 0.53). There were no significant differences between n-3 LC-PUFA and control in birth weight or length at birth. No statistically significant heterogeneity was detected for any of these analyses.
Adverse effects (reported in 3 RCTs).
One study reported similar rates of withdrawal between cod liver oil and corn oil (43.1% versus 38.7%). One study stated that significantly more women reported belching and unpleasant taste with fish oil compared with olive oil (70% versus 20% and 42% versus 7.4%, respectively, p<0.001) and significantly greater blood loss with fish oil compared with olive oil (p=0.04). One study reported that significantly more women consuming DHA from eggs reported one or more adverse events compared with women eating regular eggs (38% versus 25%, p<0.01), but serious adverse event rates were similar between treatment groups.
